Waystar Holding Corp. (WAY)
NEUTRALFundamental
60
Price
$25.21
Market Cap
$4.82B
Part 1 · What the company is worth
Overview
Waystar Holding Corp. develops a cloud-based software solution for healthcare payments. Its platform offers financial clearance, patient financial care, claim and payer payment management, denials prevention and recovery, clinical integrity and revenue capture, and analytics and reporting solutions. It primarily serves healthcare industry. The company was founded in 2017 and is headquartered in Lehi, Utah.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balance Sheet & Liquidity
Revenue
$1.21B
Trailing 12 months (through 6/30/2026)
Net Income
$135M
Trailing 12 months (through 6/30/2026)
Free Cash Flow
$283M
Total Equity
$3.88B
Total Liabilities
$1.91B
Current Ratio
1.85
Interest Coverage
-
Debt/EBITDA
3.80
Earnings Per Share
Revenue & Net Income
Free Cash Flow
Income Breakdown
Historical statement
Margins over time
Debt over time
How heavy the debt is
Growth grid
Growth — Revenue
Fair Value Estimation
Fair Value
$20.84
Current Price
$25.21
Margin of Safety
-21.0%
Fair Value Range
$13.54 - $28.13
Estimation Methods
Valuation Metrics
P/E Ratio
36.21
ROE
2.9%
P/B Ratio
1.22
P/FCF
19.74
Gross Margin
-
ROIC
3.9%
Profitability Radar
Value Creation (Economic Moat)
ROIC
3.9%
WACC
8.4%
ROIC − WACC
-4.6 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Fundamental Analysis Criteria
Passed (14)
- EPS shows upward trend
- P/FCF 19.74
- P/B Ratio 1.22
- Debt/Equity ratio
- Operating Margin 22.9%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- Analyst Consensus 93% Buy
- Earnings Surprise avg 2.5%
- Earnings Quality (OCF/NI) 2.17
- Net Margin Trend 11.2% vs 8.5%
Failed (8)
- Price CAGR -17.46%
- ROIC 3.9%
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- ROE 3.6%
- Share Dilution 24.9%
- Piotroski F-Score 4/9
Unavailable (5)
- Gross Margin NaN%
- Dividend Payout NaN%
- Interest Coverage
- Revenue Growth 5Y (Finnhub)
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Mixed signals: some areas need attention
Earnings Quality
High quality: earnings backed by cash
Share Dilution
Issuing new shares, diluting ownership
Governance
Executive Team
| Name | Title | Age |
|---|---|---|
| Mr. Matthew J. Hawkins | CEO & Director | 53 |
| Mr. Steven M. Oreskovich CPA | Advisor | 53 |
| Mr. T. Craig Bridge | Chief Transformation Officer | 52 |
| Ms. Alpana Wegner C.P.A. | Chief Financial Officer | 52 |
| Mr. Edward Akira Parker | Head of Investor Relations | - |
| Mr. Mark Encinger | Vice President of Treasury & Compliance | - |
| Mr. Gregory R. Packer | Chief Legal Officer & Secretary | 45 |
| Kristin Lee | Vice President of Communications | - |
| Mr. Brendan O'Connor | Senior Vice President of Corporate Development & Strategy | - |
| Ms. Kim Wittman | Chief People Officer | 46 |
Audit Risk
1
Board Risk
6
Compensation Risk
4
Shareholder Rights Risk
8
Part 2 · The price and when to enter
This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.
Latest News
Recent headlines for WAY, sourced from Markets Gazette.
- 3/15/2026POSITIVEWaystar Stock Is Down 32% This Past Year, but One Fund Bought Up $11.5 Million Last Quarter
Despite a 32% stock decline over the past year, Waystar Holding Corp. has attracted significant investor interest, with one fund acquiring $11.5 million worth of shares in the last quarter. Waystar, a provider of cloud-based software for healthcare payment and revenue cycle management, appears to be viewed as undervalued by this particular investor. This substantial purchase, against a backdrop of recent poor stock performance, suggests a contrarian bet on the company's long-term prospects and its position within the healthcare technology sector.
via Markets Gazette